ArticleJournal of clinical laboratory analysis2021
GC-MS metabolomics identifies novel biomarkers to distinguish tuberculosis pleural effusion from malignant pleural effusion.
Article in Journal of clinical laboratory analysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Targeted detection of amino acid profiles in pleural fluid and serum by liquid chromatography-tandem mass spectrometry for estimating the risks of four aetiologies of pleural effusion: a proof-of-concept study.Annals of medicine · 2026Article
- Metabolic biomarkers differentiate extrapulmonary tuberculosis from pulmonary TB and non-TB pleural effusions.Frontiers in medicine · 2026Article
- The Evolving Landscape of Host Biomarkers for Diagnosis and Monitoring of Tuberculosis.Biomedicines · 2025Review
- Combined urine proteomics and metabolomics analysis for the diagnosis of pulmonary tuberculosis.Clinical proteomics · 2024Article
- Comparative Metabolome and Transcriptome Analyses Reveal Molecular Mechanisms Involved in the Responses of TwoPlants (Basel, Switzerland) · 2024Article
- Variations in pleural microbiota and metabolic phenotype associated with malignant pleural effusion in human lung adenocarcinoma.Thoracic cancer · 2023Article
- Untargeted Metabolomics Based Prediction of Therapeutic Potential for Apigenin and Chrysin.International journal of molecular sciences · 2023Article
- Untargeted Metabolite Profiling of Adipose Tissue in Rats Exposed to Mepiquat.Foods (Basel, Switzerland) · 2023Article
- Biomarker discovery for tuberculosis using metabolomics.Frontiers in molecular biosciences · 2023Review
- Biomarkers identification in follicular fluid of women with OHSS by using UPLC-MS method.Frontiers in endocrinology · 2023Article
- Development and Validation of a Scoring System for Early Diagnosis of Malignant Pleural Effusion Based on a Nomogram.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundTuberculous pleural effusions (TBPEs) and malignant pleural effusions (MPEs) are two of the most common and severe forms of exudative effusions. Clinical differentiation is challenging; however, metabolomics is a collection of powerful tools currently being used to screen for disease-specific biomarkers.
methods17 TBPE and 17 MPE patients were enrolled according to the inclusion criteria. The normalization gas chromatography-mass spectrometry (GC-MS) data were imported into the SIMCA-P + 14.1 software for multivariate analysis. The principal component analysis (PCA) and orthogonal partial least-squares discriminant analysis (OPLS-DA) were used to analyze the data, and the top 50 metabolites of variable importance projection (VIP) were obtained. Metabolites were qualitatively analyzed using the National Institute of Standards and Technology (NIST) databases. Pathway analysis was performed by MetaboAnalyst 4.0. The detection of biochemical indexes such as urea and free fatty acids in these pleural effusions was also verified, and significant differences were found between these two groups.
results1319 metabolites were screened by non-targeted metabonomics of GC-MS. 9 small molecules (urea, L-5-oxoproline, L-valine, DL-ornithine, glycine, L-cystine, citric acid, stearic acid, and oleamide) were found to be significantly different (p < 0.05 for all). In OPLS-DA, 9 variables were considered significant for biological interpretation (VIP≥1). However, after the ROC curve was performed, it was found that the metabolites with better diagnostic value were stearic acid, L-cystine, citric acid, free fatty acid, and creatinine (AUC > 0.8), with good sensitivity and specificity.
conclusionStearic acid, L-cystine, and citric acid may be potential biomarkers, which can be used to distinguish between the TBPE and the MPE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.